Key Note Speaker

Mojib Latif

Mojib Latif, geb. 1954, promovierte 1987 und habilitierte 1989 in Ozeanografie an der Universität Hamburg. Seit 2003 ist er Professor für Klimadynamik an der Christian-Albrechts-Universität zu Kiel und forscht am GEOMAR Helmholtz-Zentrum für Ozeanforschung Kiel. Seit November 2017 ist er Präsident der Deutschen Gesellschaft Club of Rome, seit Januar 2022 Präsident der Akademie der Wissenschaften in Hamburg. Latif hat über 200 wissenschaftliche Veröffentlichungen und mehrere Bücher verfasst. Zahlreiche Auszeichnungen, u.a. 2000 die Sverdrup Gold Medal der Amerikanischen Meteorologischen Gesellschaft, 2015 der Deutsche Umweltpreis und 2019 die Alfred-Wegener-Medaille der Deutschen Meteorologischen Gesellschaft.

Vortragstitel: Herausforderung Klimawandel
In der Eröffnungs-Plenarsitzung am Freitag, 13.10.2023 in der Zeit von 17:15–19:00 Uhr

John Haanen

John Haanen finished his MD at Leiden University cum laude in 1988. From 1988 till 1991 he performed his PhD studies at the Division of Immunohematology & Blood Bank of Leiden University Medical Center and at DNAX, Research Institute, Palo Alto, California, US and defended his PhD thesis on human CD4+ helper T cells reactive against mycobacteria. He trained in internal medicine in hospitals in Leiden and The Hague. In 1996 he was registered as consultant internist. From 1997-1999 he did a post-doctoral fellowship at the Division of Immunology of the Netherlands Cancer Institute (NKI), Amsterdam. From 1999-2001 he trained in medical oncology and was appointed a permanent position as consultant medical oncologist and research group leader at NKI. His research has been focused on development of innovative immunotherapies in close collaboration with prof. Ton Schumacher. In 2008 he was appointed professor of translational immunotherapy of cancer at Leiden University Medical Center. From 2009 till 2018 he headed the Division of Medical Oncology at NKI. In 2018 he was appointed CSO Immunotherapy, one of the major research themes at NKI. His current research is on development of cellular therapies for solid tumors, neoadjuvant immunotherapies, and biomarker research. His clinical specialty is in melanoma and other skin cancers, kidney cancer and management of immune-related adverse events. He co- authored over 300 peer-reviewed articles, serves at the editorial board of ESMO Open, Cancer Treatment Reviews and Kidney Cancer. He is currently Editor-in-Chief of ESMO IOTECH. John Haanen was scientific co-chair of ESMO IO Congress from 2016-2019, and Scientific Chair of the ESMO 2020 Congress.

Vortragstitel: Immuno-Oncology from Checkpoint-Inhibitors to TIL and CAR-T Therapy
In der Plenarsitzung am Samstag, 14.10.2023 in der Zeit von 10:00–11:30 Uhr

Marcel van den Brink

Marcel van den Brink is a physician scientist and medical oncologist who performs both laboratory and clinical research related to allogeneic bone marrow transplantation (BMT) and immuno-oncology. He is the Head of the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center (MSKCC) and holds a joint appointment in the Immunology and Transplantation Program of the Sloan Kettering Institute. He is the Co-Director of the Parker Institute for Cancer Immunotherapy at MSKCC and Chairman of the Board of DKMS, an international nonprofit organization devoted to bone marrow donor registration. As a clinical scientist, he is involved in immunotherapeutic trials of cytokines, cell therapies, as well as strategies to manipulate the intestinal microbiome for patients with hematologic malignancies. His laboratory is devoted to the immunology of BMT and he studies immune reconstitution, pathophysiology of graft-versus-host disease, the intestinal microbiota, and chimeric antigen receptor T cells in patients and preclinical models. Both as a Division Head and a laboratory Principal Investigator, he mentors junior faculty members, hematology oncology fellows, postdoctoral fellows, graduate students, and undergraduate students.

Vortragstitel: The Role of the Intestinal Microbiome in Cancer Immunotherapy
In der Plenarsitzung am Samstag, 14.10.2023 in der Zeit von 10:00–11:30 Uhr